Iovance shares slide as lifileucel data shows mixed results across lung cancer subgroups

Key points

• Lifileucel showed a 25% overall response rate in 69 patients with advanced non-squamous non-small cell lung cancer, matching previous interim data.
• A specific subgroup of smokers without KRAS or HER2 mutations achieved a 59% response rate, accounting for over 75% of all positive outcomes in the trial.
• Patients with KRAS mutations largely did not respond to the therapy, highlighting the need for precision-based patient selection.
• Iovance will launch the POSITILITY trial in November 2026, enrolling only patients matching the high-response genetic and smoking profile.
• The company expects to complete enrollment for the current trial phase at approximately 80 patients and plans to file for FDA approval in 2027.
• Shares dropped 15% initially before recovering to a 6% loss, with pre-market trading showing an 8.9% decline due to profit-taking and valuation concerns.

Background

Iovance’s financial health is heavily dependent on its approved therapy, Amtagvi, which generated $91 million of the company’s $99.3 million revenue in the second quarter of 2026. While the company remains unprofitable with an operating loss of $51.9 million, it has improved margins and reduced losses compared to the previous year. The recent stock volatility occurs against a backdrop of rising interest rates and a broader market pullback in high-multiple biotech stocks. Recent industry developments, such as Amgen’s successful small cell lung cancer trial and Verastem’s KRAS inhibitor data, underscore the competitive landscape in oncology treatments.

How outlets are covering it

Investing.com and Yahoo Finance reported the stock decline as a reaction to the detailed trial data, noting that the overall 25% response rate met expectations but failed to excite investors due to the lack of broad efficacy. Investing.com emphasized the 'buy the rumor, sell the news' dynamic, pointing out that the stock had risen 12% the previous day on the announcement of positive results, leading to profit-taking. Trefis focused on the company’s reliance on Amtagvi for revenue and questioned whether the current valuation, at 20.5 times sales, justifies the risk, especially given the company’s continued losses. Trefis noted that while Amtagvi sales are growing, the lifileucel data’s mixed results could impact investor confidence in the pipeline. All sources agree that the next catalyst will be the November 2026 launch of the POSITILITY trial and the Q3 earnings report on November 5, 2026.

Why it matters

The lifileucel data highlights the growing importance of biomarker-driven patient selection in cancer therapy. The significant difference in response rates between subgroups suggests that future approvals may be restricted to specific genetic profiles, potentially limiting market size but improving efficacy. For Iovance, the success of the POSITILITY trial is critical to securing FDA approval and expanding its pipeline beyond Amtagvi. The stock’s volatility also reflects broader market sensitivities to biotech valuations in a high-interest-rate environment, where investors are demanding clearer paths to profitability and robust clinical data.

What to watch

Iovance will begin enrolling patients in the POSITILITY trial in November 2026, focusing on smokers without KRAS or HER2 mutations. The company expects to finalize enrollment for the current Phase 2 trial at approximately 80 patients. A supplemental filing with regulators is planned for 2027, potentially targeting non-squamous non-small cell lung cancer. Investors will closely watch the Q3 earnings report on November 5, 2026, for updates on Amtagvi revenue and overall financial performance. The market will also assess whether the stock’s pullback is a temporary reset or a sustained correction based on the durability and safety data presented in the webcast.